Drug combo for newly diagnosed mixed phenotype acute leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination of two drugs — a Bcl-2 inhibitor (which helps leukemia cells die) and azacitidine (a medicine that helps the bone marrow make normal blood cells) — for people newly diagnosed with mixed phenotype acute leukemia. The goal is to see if this combination is safe and effective for this rare type of leukemia.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged between 16 and 70 years old.
- Recently diagnosed with mixed phenotype acute leukemia (MPAL) — a rare type of leukemia that has features of both myeloid and lymphoid leukemia.
- No prior treatment for leukemia, except a short course of steroids or hydroxyurea (up to 7 days) to control blood counts.
- Physically able to manage daily activities (score of 0–3 on a standard scale).
- No major heart, brain, lung, liver, or kidney problems that would make the treatment unsafe.
- Willing to sign a consent form to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment for adults with a rare type of leukemia that has both myeloid and lymphoid features and is positive for the CD19 marker. It aims to see if this treatment can help people who have not been treated yet for this condition.
This trial tests a new drug combination (bleximenib, venetoclax, and azacitidine) for people with a specific genetic type of AML who cannot receive strong chemotherapy. The goal is to see if this combination is safer and more effective.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
This trial tests a combination of low-dose chemotherapy and immune-targeted drugs for adults newly diagnosed with a specific type of leukemia. The goal is to find a treatment that is effective with fewer side effects.
This study tests a new drug called BL-M11D1 combined with standard chemotherapy (cytarabine + daunorubicin) or a targeted therapy (venetoclax + azacitidine) for people with newly diagnosed acute myeloid leukemia (AML). It aims to see if this combination is safe and effective.
Hear when a new Newly Diagnosed Mixed Phenotype Acute Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.